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Parkinson's Disease (PD) is a progressive neurodegenerative and movement disorder 
primarily caused by the degradation of dopaminergic neurons. Known markers of 
neurodegeneration in PD are Lewy Bodies, which are fibrillar aggregates that are found in the 
brains of PD patients. Lewy Bodies can accumulate from specific mutations in the SNCA gene 
that codes for alpha-synuclein, a protein enriched in presynaptic neurons. A mutated SNCA gene 
can cause conformational aggregates of alpha-synuclein to form toxic species mediating 
neuronal death. Research into alpha-synuclein has led to the discovery of a binding partner 
known as synphilin-1 that is also found in protein aggregates including Lewy Bodies in neurons 
of PD patients. Proteasomal pathways and autophagy are known to control the degradation of 
alpha-synuclein and synphilin-1 to moderate this cellular toxicity. How the cytosolic inclusions 
of synphilin-1 and alpha-synuclein are related to changes in the degradation of these proteins is 
debated. Furthermore, little is known about the physiological function of synphilin-1 or its role in 
pathogenesis. This literature review will synthesize existing research regarding synphilin-1’s role 










Parkinson's Disease (PD) is a progressive neurodegenerative disorder resulting from the 
degradation of dopaminergic neurons. Deficiency in dopamine production can lead to chronic 
motor problems such as tremors and rigidity. Non-motor problems may also persist and include 
cognitive impairment. Mostly sporadic in nature, PD cases can also come in familial forms from 
mutations in a variety of extensively studied genes like SNCA/PRKN1, PRKN2, PTEN-induced 
putative kinase 1 (PINK1), Daisuke-Junko1 (DJ1), and leucine-rich repeat kinase 2 (LRRK2) 
(Ganguly et al.  2018). These mutated genes contribute to disruption of autophagy and the 
proteosome. Autophagy plays the role of clearing misfolded protein aggregates using double 
membraned, autophagic vacuoles (Glick et al. 2010). The proteosome also clears ubiquitinated 
misfolded proteins (Lim et al. 2007). While existing treatments control motor symptoms, there 
are still no therapeutics that help stop the progression of the disease. Research is developing to 
find new ways to target genetic markers and mechanisms on the molecular level to halt the onset 
and progression of PD. Some of this research stems from the molecular physiology of a protein 
known as alpha-synuclein that is encoded by SNCA. The expression levels and mutations of 
SNCA play critical roles in the pathogenicity of PD. 
Alpha-synuclein is enriched in presynaptic terminals and has been shown to aggregate in 
the form of Lewy Bodies, which are known to be a histological hallmark of PD that contributes 
to some level of cell toxicity in PD patients. They can be widely distributed in the central 
nervous system, especially dopaminergic neurons that have a significant impact on the pathology 
of PD (Gomez-Benito et al. 2020). Overexpression of SNCA has been shown to make 
dopaminergic neurons vulnerable to degradation (Tagliafierro et al. 2016). Transgenic mouse 
lines overexpressing SNCA have motor impairments and decreased neurotransmission of 
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dopamine (Tagliafierro et al. 2016). An increase in Lewy Bodies in the brains of PD patients can 
also be a result of specific point mutations in the SNCA gene that affect alpha-synuclein’s 
quaternary structure. A mutated SNCA gene results in a misfolded alpha-synuclein protein that is 
more susceptible to forming toxic oligomers or aggregates  (Gomez-Benito et al. 2020). Alpha-
synuclein’s physiological role is still unclear, but it is highly involved in the progression of PD in 
patients. 
Research into alpha-synuclein has led to the discovery of the binding partner synphilin-1 
that is also found in protein aggregates including LBs in neurons of PD patients. Synphilin-1 
overexpression can lead to accumulation of synphilin-1 aggregates (Engelender et al. 1999). 
Since synphilin-1 is an intrinsic component of Lewy Bodies, its association with alpha-synuclein 
highlights a potentially pathological role (Ribeiro et al. 2002). Like alpha-synuclein, synphilin-1 
is widely distributed in the central nervous system and its physiological role is uncertain. It is 
hypothesized that synphilin-1 may have its synaptic roles modulated by alpha-synuclein during 
synaptic vesicle trafficking (Burré et al. 2015). In addition, synphilin-1 has both cytoprotective 
and cytotoxic effects in neurons when binding to alpha-synuclein that are being currently 
investigated. Experimental data has shown that misfolded synphilin-1 proteins that aggregate 
pose cytotoxicity in neuronal cells, yet Lewy Bodies in association with wild type synphilin-1 
can serve to help eliminate toxic syphilin-1 aggregates (Tanaka et al. 2004). Clearly, there is 
conflicting data on synphilin-1’s physiological role as research in PD pathogenesis continues.  
A balance between synthesis and degradation of cellular proteins is necessary for cell 
survival, and this is done through proteasomal pathways and autophagy. In the case of PD, 
proteasomal pathways and autophagy are known to clear alpha-synuclein aggregates as well as 
synphilin-1 to moderate the cell toxicity in PD patients. The ubiquitin proteosome pathway 
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utilizes ligases to ubiquitinate unwanted proteins as shown in Figure 1. In the case of PD, two of 
the most important E3 ligases that exists in eukaryotic cells are SIAH-1 and SIAH-2 that 
ubiquitinate synphilin-1 and alpha-synuclein for it to be degraded by the proteosome (Liani et al. 
2004). Overexpression of synphlin-1 in transgenic mice can actually promote proteostasis of 
alpha-synuclein (Casadei et al. 2014). In addition to the ubiquitin-proteosome pathway, 
autophagy also serves the purpose of removing protein aggregates that accumulate in the cell 
(Zhang et al. 2012). Autophagy is activated upon cellular stress. In general, the three types of 
autophagy are macroautophagy, microautophagy, and chaperone mediated autophagy (CMA). 
Macroautophagy is a multistep process that forms double membrane structures called 
autophagosomes that fuse with lysosomes containing proteins to be degraded. Microautophagy is 
the selective degradation of intracellular constituents that are directly invaginated by lysosomes. 
Chaperone mediated autophagy uses chaperones that recognize target proteins to be delivered to 
lysosomes to be degraded (Zhang et al. 2012). Both the proteosome and autophagy are important 
factors in regulating PD as they serve to modulate synphilin-1 levels that may contribute to 
pathogenesis.  
Synphilin-1 can form aggregates while interacting with alpha-synuclein to promote the 
progression of disease in PD patients. While its mechanisms are not fully understood, synphilin-
1 has a significant physiological role. In addition to its effects on intracellular degradation, 
synphilin-1 can form enough cytosolic inclusions to impair essential dopaminergic neuronal 
synapses that are responsible for several motor and nonmotor functions (Engelender et al. 1999). 
Synphilin-1 also demonstrates ambiguous functions when interacting with alpha-synuclein that 
either enhances or worsens cell survival. Elucidating synphilin-1’s impacts will have to start 
from understanding its discovery, its interactions with alpha-synuclein, and how it is involved in 
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autophagy and the proteosome. This literature review will highlight these important aspects of 








Section I: Parkinson’s Disease and Alpha-synuclein’s Contribution to Pathogenesis 
Parkinson’s Disease (PD) has several pathological markers and clinical features not fully 
understood. A common neurodegenerative disease second only to Alzheimer’s disease, PD has a 
high prevalence among the older population. Tremors, rigidity, and bradykinesia are some of the 
most prevalent symptoms that older PD patients can experience. Before PD pathologically 
progresses into severe clinical symptoms, there is a premotor or prodromal phase of the disease 
(Kouli et al. 2018). The prodromal phase of PD has been shown to start at peripheral structures 
of the nervous system causing a host of symptoms including constipation, restlessness, rapid eye 
Figure 1.  Ubiquitin-Proteosome system is responsible for the degradation of 
ubiquitinated proteins: the first diagram shows E1 and E2, where E2 is the ubiquitin-
conjugating enzyme to which the ubiquitin is transferred from the E1. E3 is the ubiquitin 
ligase that ubiquitinates the target protein. This ubiquitinated protein gets degraded by the 




movement, and depression. These symptoms may last for several years and often go undiagnosed 
as PD until motor symptoms arise. The prodromal state of PD is perceived as an ideal time for 
therapeutic intervention as it is such an early stage of the disease that it has not impacted the 
motor sensory neurons that cause the tremors, rigidity, and bradykinesia. However, clinical 
diagnosis of PD generally occurs at the time the patient presents with motor problems. Currently, 
the best tool medical practitioners use to diagnose PD is the onset of motor problems and patient 
response to levodopa treatment (Armstrong et al. 2020). More improvements in alternative 
treatments and early diagnosis of symptoms are being pursued every day. 
The etiology of PD is multifactorial, having both genetic (familial) and environmental 
(sporadic) factors contributing to the progression of the disease. Familial and sporadic PD have 
been shown to lead to similar phenotypes. Most cases are sporadic but about 15% come familial 
and have generally the same progression of neurodegeneration (Armstrong et al. 2020). Specific 
genetic mutations in PARK genes have been identified to potentially contribute to PD 
pathogenesis. These PARK genes include SNCA/PARK1 (encoding alpha-synuclein), PARK2 
(Parkin), PINK1, DJ-1, and LRRK2. The rest of the cases that form sporadic PD may come from 
factors such as age, smoking, and diet. Thus, the environment is a major contributor to PD. Age 
is the biggest environmental risk factor, with a median age of 60 having onset of PD. Cohort 
studies have shown pesticides, herbicides, and heavy metals to significantly contribute to onset 
of PD, while the mechanisms to how they do so are not fully understood. 
Besides the motor symptoms mentioned previously, PD has several pathogenic impacts to 
the cell including mitochondrial dysfunction, defective protein clearance mechanisms, and 
neuroinflammation. Many of these processes can be understood from knowing how alpha-
synuclein operates in dopaminergic neurons. Alpha-synuclein and Lewy Body formation can be 
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found both in the central nervous system and peripheral nervous system (Stefanis et al. 2012). 
The native structure of alpha-synuclein is soluble and mostly unfolded and thus not so 
susceptible to aggregation (Ostrerova-Golts et al. 2000). However, misfolding can cause alpha-
synuclein to adopt a beta sheet rich amyloid structure that is predominantly found in Lewy 
Bodies. Amyloid structures are secondary structures held by hydrogen bonding and come in 
fibrillar aggregates to cause neurodegenerative disorders (Gómez-Benito et al. 2020). Misfolding 
may occur due to the well-studied A30P and A53T point mutants of alpha-synuclein. 
Aggregation of mutated alpha-synuclein has been found to be more pronounced in A53T mutants 
than A30P mutants in transfected BE-M17 neuroblastoma cells, but cellular mechanisms work to 
clear the toxicity resulting from these proteins (Ostrerova-Golts et al. 2000). The two major 
clearance systems humans use are the ubiquitin-proteosome pathway that ubiquitinates abnormal 
proteins for degradation by the proteosome and autophagy, which is the process of delivering 
organelles or damaged proteins engulfed in double-membraned vesicles to lysosomes (Kouli et 
al. 2018). There are clearly several events impacted by PD which hinder normal function of a 
dopaminergic neuronal cell. 
Alpha-Synuclein may be modified by phosphorylation, oxidation, nitrosylation, 
glycation, or glycosylation. Of all such modifications, the best studied is phosphorylation. 
Phosphorylation of alpha-synuclein at S129 was observed to contribute to alpha-synuclein 
mediated toxicity in cells of PD patients (Li et al. 2020). However, there has been some 
conflicting evidence to suggest a protective role for phosphorylated alpha-synuclein. Either way, 
the presence of phosphorylated alpha-synuclein is greater in the brains of PD patients than those 
of healthy brains. This phosphorylation has also been shown to modulate membrane binding by 
alpha-synuclein (Stefanis et al. 2019). Posttranslational modifications of alpha-synuclein prove 
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to be another important area of study in PD pathogenesis besides the A53T and A30P point 
mutations of alpha-synuclein due to the implications phosphorylated alpha-synuclein has on 
degradation of dopaminergic neurons. 
Section II: The Discovery of Synphilin-1 
Alpha-synuclein is clearly an important component of Lewy bodies, but the discovery of 
synphilin-1 has opened new pathological inquiries for PD. Synphilin-1 was found to be an 
intrinsic component of Lewy bodies while acting as a binding partner to alpha-synuclein. This 
interaction may be a key element to the aggregation of cytosolic inclusions and the eventual 
degradation of dopaminergic neurons (Engelender et al. 1999). The regions of synphilin-1 that 
were most notably found to bind to alpha-synuclein were the N terminus and its central region. 
Deleting the first 349 amino acid residues of the N terminal region of synphilin-1 abolishes its 
interaction with alpha-synuclein (Engelender et al. 1999). This study went on to demonstrate the 
colocalization of alpha-synuclein and synphilin-1 in neurons.  
The SNCAIP gene that encodes synphilin-1 has been mapped out through extensive 
research (Engelender et al. 1999). The SNCAIP locus is within the q arm of chromosome number 
5 and contains polymorphic repeats of GT nucleotides. The SNCAIP gene has an open reading 
frame containing 10 exons. Exons 4 through 7 encode ankyrin-like repeats and the coil domain 
of synphilin-1. There is also a GTP and ATP binding domain in synphilin-1. When bound to 
ATP or GTP, synphilin-1 is more prone to aggregate and bind to alpha-synuclein (Engelender et 
al. 2000). The data collected on synphilin-1’s structure contributes to an understanding of its 
physiological role that is continually researched.  
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Subsequent experiments demonstrating syphilin-1’s interaction with alpha-synuclein 
came from co-immunoprecipitation experiments with glutathione S-transferase (GST) fusion 
proteins (Engelender et al. 1999). Wild-type, A30P, and A53T mutated alpha-synuclein GST 
fusion proteins were incubated with HEK 293 cells transfected with synphilin-1. Synphilin-1 co-
precipitated with alpha-synuclein to confirm their interactions with each other, but synphilin-1 
did not interact with a GST protein alone. Co-transfection of constructs encoding synphilin-1 and 
a portion of alpha-synuclein in HEK 293 cells has also been found to cause the formation of 
cytosolic inclusions. (Engelender et al. 1999). These experiments suggest synphilin-1 is a direct 
binding partner to alpha-synuclein. 
Further research has looked into synphilin-1’s interaction with alpha-synuclein amidst 
synaptic vesicle trafficking between dopaminergic neurons. Synphilin-1 is already known to be a 
regulator of synaptic vesicle trafficking (Burré et al. 2015). Some experiments have measured 
the degree of association between synaptic vesicles and synphilin-1 by immunoprecipitation. 
Synphilin-1 is strongly associated with synaptic vesicles and in vitro binding experiments have 
shown this association to be resistant against high salt washing (Ribeiro et al. 2002). Because 
synphilin-1 is found to have co-immunoprecipitated with synaptic vesicles, there may be an 
important role for synphilin-1 to direct vesicular structures across synapses. However, what is 
not well understood is how synphilin-1’s influence on synaptic vesicles would be impacted by 
alpha-synuclein and its mutated forms (Burré et al. 2015). Previous claims have suggested alpha-
synuclein anchors synphilin-1 to synaptic vesicles, but levels of immunopurified alpha-synuclein 
on these vesicles were undetectable (Ribeiro et al. 2002). Purified alpha-synuclein added to a 
mixture of synaptic vesicles and synphilin-1 however showed that alpha-synuclein, both wild 
type and A53 mutant, can modulate synphilin-1 binding with vesicles. Alpha-synuclein was 
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discovered to break synphilin-1’s association with synaptic vesicles. Thus, synphilin-1’s 
association with synaptic vesicles is negatively modulated by alpha-synuclein (Ribeiro et al. 
2002). Alpha-synuclein may have a way of modulating synaptic vesicle trafficking while 
interacting with synphilin-1. Some of the effects alpha-synuclein can have in modulating 
synaptic vesicle trafficking were discovered to include loss of presynaptic proteins, decrease of 
neurotransmitter release, redistribution of SNARE proteins, enlargement of synaptic vesicles, 
and inhibition of synaptic vesicle recycling (Burré et al. 2015). Synaptic vesicle release is 
another significant pathological indicator of PD caused by alpha-synuclein’s interaction with 
synphilin-1. 
Section III: Clearance of Aggregated proteins by Autophagy and the Proteosome   
Autophagy and the proteosome are central players that modulate synphilin-1 levels in 
cells of PD patients. Both autophagy and the proteosome accomplish the task of degradation of 
protein aggregates, but there is a contrast in the type of proteins they target. Autophagy is seen to 
contribute to the degradation of materials that are larger in size while the proteasome handles 
degradation of short-lived proteins (Lilienbaum et al. 2013). Autophagy is regarded as a way for 
cells to combat stress in a variety of situations and they use key regulatory proteins to manage 
them.  mTOR, a protein complex that maintains balance between cellular catabolism and 
anabolism, is one of these master regulatory proteins that inhibits autophagy through its 
inhibitory effects on a protein kinase known as Ulk1 (Zhu et al. 2019). Ulk1 initiates 
macroautophagy and drives formation of autophagosomes (Yan et al. 2017). Autophagy is 
increased in cells under nutrient deprivation and other stresses. The ubiquitin-proteosome system 
consists of two steps: ubiquitination and proteasomal degradation. Ubiquitination is carried out 
through an enzymatic cascade that attaches ubiquitin to target proteins (Liani et al. 2004). The 
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attached ubiquitin acts as a signal and are targeted to the proteosome that acts as a major 
pathway for degradation of cytosolic, nuclear and membrane target proteins in all eukaryotic 
organisms (Livneh et al. 2016). SIAH-1 and SIAH-2 ligases are among the most relevant E3 
ligases that ubiquitinate alpha-synuclein and synphilin-1. SIAH-1 is primarily responsible for the 
ubiquitination of synphilin-1 whereas SIAH-2 is responsible for ubiquitination of alpha-
synuclein (Liani et al. 2004). Clearing aggregates through the ubiquitin-proteosome system and 
autophagy holds tremendous capabilities in halting PD pathogenesis. 
Autophagy is critical in PD patients, as there is found to be an accumulation of 
autophagic vacuoles in the brain when there is an accumulation alpha-synuclein (Winslow et al. 
2010). Insufficient fusion of these vacuoles with lysosomal compartments is a leading 
explanation to the abundance of cellular toxins in the cytosol of neuronal cells. Mice with 
genetically downregulated autophagy proteins have been shown to exhibit the same 
neurodegenerative patterns as PD patients, thus suggesting the neuroprotective role autophagy 
has against pathogenesis (Wan et al. 2020). Several experimental models explain the protection 
autophagy offers for cell survival. Some of these models include using animals to induce 
cytotoxicity in cells to activate autophagy with specific compounds (Zhang et al. 2012).  
Some experiments have shown the capabilities of autophagy to clear alpha-synuclein 
from cells. For example, a stable PC12 cell model with induced macroatuophagy was found to 
degrade A53T mutated alpha-synuclein (Webb et al. 2003). Wild type alpha-synuclein and an 
A30P mutant of alpha-synuclein were also degraded but mostly through the proteosome (Webb 
et al. 2003).  Pharmocological induction of macroautophagy with drugs like rapamycin is also 
capable of degrading wild type, A53T, and A30P mutated alpha-synuclein (Stefanis et al. 2019). 
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Autophagy is an important line of defense against alpha-synuclein aggregates, hence why 
research in this field could pave way for novel autophagy induced treatments for PD patients. 
CMA is another primary pathway alpha-synuclein is cleared within cells, and any 
induction of this pathway has therapeutic advantages to PD patients.  Alpha-synuclein is 
recognized by chaperones when they are destined for degradation by CMA (Tofaris et al. 2003). 
With the assistance of chaperones, alpha-synuclein binds lysosomal-associated membrane 
protein type 2A (LAMP-2A). Lysosomes are able to uptake alpha-synuclein for degradation, and 
it has been demonstrated that knockouts of LAMP-2A leads to an increase of cytosolic alpha-
synuclein (Martinez-Vicente et al. 2008). While CMA has ways of degrading alpha-synuclein, 
there are some factors like mTOR that can downregulate chaperone mediated autophagy. 
Pharmacologically inhibiting mTOR would help increase CMA and lower alpha-synuclein 
aggregates in the cell (Moors et al. 2017). In brief, we can see CMA offers another opportunity 
for alpha-synuclein to be degraded. 
Dysfunction in the proteosome has been implicated in PD as well. Alpha-synuclein 
evidently promotes the dysfunction of the proteosome which can lead to the further accumulation 
of alpha-synuclein aggregates (Lim et al. 2007). A dysfunctional ubiquitin-proteasome system 
has been shown to lead to dopaminergic neuronal death (Lim et al. 2007). Clearing toxic species 
that result from accumulated alpha-synuclein aggregates can increase ubiquitin-proteasomal 
activity and ensure proper disposal of ubiquitinated proteins. 
Section IV: Inhibition of Autophagy and the Proteosome due to Alpha-Synuclein 
Accumulation of wild type and mutated alpha-synuclein has been shown to disrupt 
autophagy and has been determined to be done through the influence over Rab1a. Rab1a is a 
14 
 
small GTPase protein that regulates vesicle trafficking, including in autophagy. Alpha-synuclein 
has been determined to disrupt autophagy, but additional studies have shown its ability to inhibit 
Rab1a to impact a cell’s secretory pathway (Winslow et al. 2010). Alpha-synuclein 
overexpression experiments have been shown to decrease autophagy based on lower levels of 
LC3-II. LC3-II, a soluble microtubule-associated protein, comes from an LC3-I conjugated to 
phosphatidylethanolamine that is recruited to autophagosomes. LC3-II is a reliable marker for 
autophagy because it is involved in the final stages of autophagosome maturation, and is 
recycled during lysosomal degradation (Tanida et al. 2008). While research into alpha-synuclein 
overexpression has been determined to decrease vesicle count, additional studies have pursued 
the effect of co-overexpression with Rab1a (Gitler et al. 2008). If Rab1a is overexpressed in a 
cell that has impaired autophagy from overexpression of alpha-synuclein, autophagy is rescued 
and aggregates of alpha-synuclein in the cytoplasm were found to be degraded (Winslow et al. 
2010). Rab1a therefore has significant implications in PD patients with overexpressed alpha-
synuclein.  
Alpha-synuclein was also found to increase levels of insoluble p62 proteins. p62 is a 
classical receptor in autophagy and is involved in the proteasomal degradation of proteins. (Shin 
et al. 2020). p62 can colocalize with LC3 during autophagy. LC3-II conversion triggers 
autophagosomes to engulf target proteins. p62 turnover and protein amount is a reliable source in 
measuring the activity of autophagy. (Tanida et al. 2008). However, p62 is not able to colocalize 
with autophagosomes with overexpressed alpha-synuclein and results in a decrease in vesicle 
count (Shin et al. 2020). Alpha-synuclein therefore has an impact on autophagy through its 
effects on p62 proteins. 
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Additional experiments have studied Atg9 as another protein to induce autophagy. Atg9 
is an autophagy related protein that directs membranes from donor organelles to form autophagic 
vacuoles (Winslow et al. 2010). Atg9 normally localizes with the trans-Golgi network, but 
autophagy induced cells trigger Atg9 localization with LC3-II positive autophagosomes. Studies 
that overexpressed alpha-synuclein found that Atg9 was mislocalized in the cell, and 
autophagosome vesicles were greatly reduced (Lynch-Day et al. 2010). A model supports that 
Rab1a functions through Atg9. The consensus is that alpha-synuclein will inhibit Rab1a activity 
and Atg9 colocalization. Rab1a is thought to operate upstream in autophagy formation, and 
consequently have influence over Atg9. Experiments show that overexpression of alpha-
synuclein and a knockdown of Rab1a will mislocalize Atg9 and cause fewer LC3-II vesicles 
(Winslow et al. 2010). Atg9 is an important protein that needs to be localized properly for 
mediating cell toxicity from alpha-synuclein. 
Although alpha-synuclein overexpression has been shown to decrease autophagy, studies 
have gone to observe the effect on autophagy from A53T and A30P point mutants of alpha-
synuclein. The A30P mutated alpha-synuclein specifically is known to inhibit chaperone 
mediated autophagy (Lei et al 2019). One of the foundational pieces of knowledge on autophagy 
pathways is when one is impaired, another compensatory autophagy pathway is upregulated. 
Thus, experiments have shown that macroautophagy is upregulated upon impairment of 
chaperone mediated autophagy (Lynch-Day et al. 2010). The exact mechanism of chaperone 
mediated autophagy inhibition done by alpha-synuclein has to do with a transcriptional repressor 
ZKSCAN3. ZKSCAN3 represses transcription of several autophagy proteins including LC3, 
Ulk1, and WIPI2 and its activation contributes to significant loss of autophagosomes and 
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autophagy markers like p62 (Lei et al. 2019). Thus, alpha-synuclein may be an enhancer of 
ZKSCAN3 expression. 
Alpha-synuclein can not only exert inhibitory effects on autophagy but the proteosome as 
well. Proteasomal impairment inhibition by wild type and mutated alpha-synuclein has been 
speculated as either an allosteric or noncompetitive inhibition of the chymotrypsin like 20S 
protein core of the proteosome. Figure 2 depicts the result of misfolded proteins on the 
proteosome ubiquitin system. The proteosome in dopaminergic cells is largely made up of 26S 
proteosomes with 20S proteasomal subunits that have a binding affinity towards alpha-synuclein 
(Zondler 2017). While the exact method of binding to 20S proteasomal proteins is unclear, the 
amyloid structure of alpha-synuclein has a significant influence in its capabilities of inhibiting 
proteostasis.  
Figure 2 Proteostasis is impaired when protein aggregates accumulate: The diagram at 
the left hand side depicts proper degradation of protein aggregates with synphilin-1. 
Synphilin-1 proteins are depicted in green and are ubiquitinated by the purple circles drawn in 
the diagram. They are then degraded by the proteasome. Autophagosomes and lysosomes are 
also depicted in the diagram at the left hand side with synphilin-1 lysed in the containing 
vesicle. The diagram at the right hand side depicts protein misfolding and aggregation in 
green. These misfolded proteins are shown to accumulate in the cytosol when proteostasis is 
impaired. Some of these aggregates can accumulate in autophagosomes as well. This 
illustration was created by Nadine Lebek. 
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Section V: Drug Treatments 
Novel drug treatments are currently being pursued to halt the progression of PD in 
patients. The drug treatments that impact autophagy affect certain intermediates of the autophagy 
pathway. As discussed earlier, alpha-synuclein inhibits the proteosome, CMA, and 
macroautophagy, leading to further accumulation of alpha-synuclein aggregates. Different drug 
treatments can intervene at certain biochemical pathways to disrupt or promote autophagy. Most 
of these drug treatments discovered to modulate autophagy manipulate mTOR. mTOR is the 
master regulator of autophagy by its inhibitory effects on Ulk1 kinase. However, AMPK, a key 
enzyme that maintains cell homeostasis, can activate Ulk1 and inhibit mTOR to promote 
macroautophagy. AMPK is known to increase autophagy levels in cells in the presence of higher 
ADP levels (Zhu et al. 2019). Rapamycin is one drug that acts on autophagy by targeting mTOR. 
Rapamycin’s inhibitory effect on mTOR gives opportunity for autophagy to proceed by activated 
kinase Ulk1. Aggregates of alpha-synuclein can therefore be degraded in rapamycin treated cells 
and lower the risk of dopaminergic neuronal loss in PD patients. Rapamycin has been found to 
decrease the expression of alpha-synuclein, likely from the effects of upregulated autophagy 
(Zhu et al. 2019). Little data exists on rapamycin treatment effects on synphilin-1. Other drug 
treatments that have been researched to have influence on certain steps of the autophagy pathway 
are chloroquine and Metformin.  
Metformin serves as a viable therapeutic strategy for PD by inducing autophagy. 
Experiments have shown Metformin to decrease phosphorylation of alpha-synuclein in 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated mice that would otherwise contribute to cell 
toxicity and dopaminergic neuronal loss (Sportelli et al. 2020). Metformin can induce autophagy 
from increasing AMPK activity levels while inhibiting mTOR. Consequently, LC3-II has been 
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shown to increase and p62 protein levels decrease in response to Metformin treatments in 
cultured MN9D cells (Yan et al. 2017). Metformin has also been shown to fix mitochondrial 
impairment. One of the symptoms of PD is mitochondrial dysfunction, which leads to the 
production of toxic reactive oxygen species that destroys the host cell (Mor et al. 2020). A small 
degree of mitochondrial impairment has been shown to be linked to deficient E3 ligase activity 
from SIAH-1 which is responsible for ubiquitinating synphilin-1 (Dawson et al. 2010). 
Metformin has been suggested to reduce reactive oxygen species, but has also been studied to 
induce autophagy indirectly by acting on Complex I of the electron transport chain in the 
mitochondria. Metformin inhibits Complex I which results in reduced ATP production by ATP 
synthase, thus activating AMPK (Mor et al. 2020). Metformin inhibits phosphorylation of alpha-
synuclein by several kinases such as G-coupled protein receptors and casein kinases. Since 
phosphorylated alpha-synuclein has been shown to lead to cell toxicity, Metformin would 
decrease the further accumulation of alpha-synuclein aggregates. Little data exists on 
Metformin’s effect on synphilin-1, but there is data that suggests that phosphorylated synphilin-1 
can promote autophagy (Li et al. 2020). More research needs to be conducted to explore 
phosphorylated synphilin-1’s effects on autophagy, but Metformin is considered a viable drug 
treatment to increase autophagy in PD patients. 
Chloroquine is known to reduce autophagy by acting on lysosomal pH. It will raise the 
pH of lysosomes that are predestined to form autophagosomes (Mauthe et al. 2018). Lysosomes 
that have a pH raised too high are unable to properly degrade proteins, causing complications in 
the cell such as contributing to a toxic environment. Chloroquine is often used to mimic 
dysfunctional autophagy in a cell and the results are comparable to that of a cell with 
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accumulated alpha-synuclein aggregates (Gao et al. 2019). Chloroquine serves as a viable 
positive control for most experiments to analyze the impact of impaired autophagy. 
Future Directions 
Further experiments need to understand alpha-synuclein and its interactions with 
synphilin-1 in vivo and in vitro with drug treatments. Synphilin-1’s overarching effects on 
autophagy under chloroquine, Metformin, and rapamycin drug treatments are still unknown as 
well. There needs to be a comprehensive model demonstrating which drugs have an effect on 
synphilin-1 or vice versa. There should also be future experiments measuring cell death 
according to different expression levels of synphilin-1 under each drug treatment. mTOR is 
important in maintaining cellular homeostasis while regulating autophagy but little is known 
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